Shattuck Labs is a clinical-stage biotech with a preclinical pipeline, resulting in zero revenue over the last six quarters and a consistent quarterly cash burn exceeding $12M.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | -$0.14-40.0% vs -$0.10 | — vs $33,333 |
Q3 2026 Aug 11, 2026 | -$0.12+3.3% vs -$0.12 | — vs — |
Q2 2026 May 7, 2026 | -$0.13+7.1% vs -$0.14 | — vs — |
Q2 2026 Mar 5, 2026 | -$0.12+0.0% vs -$0.12 | — vs $250,000 |
Shattuck Labs (NASDAQ: STTK - Get Free Report) and Exicure (NASDAQ: XCUR - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability. Risk and Volatility Shattuck Labs has a beta
AUSTIN, Texas and DURHAM, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced two upcoming poster presentations at United European Gastroenterology (UEG) Week 2026, taking place October 17–20, 2026, in Barcelona, Spain.
Shattuck Labs, Inc. (NASDAQ: STTK - Get Free Report) shares fell 5.3% during mid-day trading on Monday. The company traded as low as $6.33 and last traded at $6.3760. 599,094 shares traded hands during mid-day trading, a decline of 37% from the average session volume of 954,866 shares. The stock had previously closed at $6.73. Wall
Shattuck Labs, Inc. (NASDAQ: STTK - Get Free Report)'s stock price traded up 11.9% on Wednesday. The stock traded as high as $6.89 and last traded at $7.3150. 221,063 shares were traded during mid-day trading, a decline of 76% from the average session volume of 928,544 shares. The stock had previously closed at $6.54. Analyst Ratings
Benchmark STTK against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Shattuck Labs, Inc. (STTK)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.62 | $417.52M | -12.50 | -82.52% | -4880.9% | -46.46% | — | |
| $18.28 | $2.3B | -5.23 | -4.26% | -445% | -90.04% | — | |
| $30.53 | $6.3B | -11.66 | — | -7585.86% | -69.59% | — | |
| $7.15 | $297.74M | 21.19 | 10.37% | 20.98% | — | — | |
| $1.73 | $123.77M | -1.00 | — | — | -48.58% | — | |
| $0.91 | $1.77M | -0.09 | -13.43% | -490.33% | -1035.26% | — |
Shattuck Labs, Inc. (STTK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Shattuck Labs, Inc. (STTK) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 11, 2026·SEC
Jun 11, 2026·SEC
Jun 9, 2026·SEC
Get notified when STTK posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Shattuck Labs, Inc. (STTK) stock FAQ — growth, dividends, profitability & financials explained
Shattuck Labs, Inc. (STTK) reported $1.0M in revenue in fiscal year 2025. That is 96% less than the $22.4M of fiscal year 2018.
Shattuck Labs, Inc. (STTK) revenue fell by 100.0% over the trailing twelve months, compared with the twelve months before.
No. Shattuck Labs, Inc. (STTK) reported a net loss of $67.7M over the trailing twelve months.
Shattuck Labs, Inc. (STTK) had a return on equity (ROE) of -46.5% over the trailing twelve months. A negative ROE means the company lost money over the period.
Shattuck Labs, Inc. (STTK) had negative free cash flow of $49.8M over the trailing twelve months.
